PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
- Known as:
- PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
- Catalog number:
- GSBA400
- Product Quantity:
- 400 preps/kit
- Category:
- -
- Supplier:
- NanoHelix
- Gene target:
- PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
Related genes to: PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(+)_1_(9_Fluorenyl)ethyl chloroformate 0.5 w_v% solution in ac(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: PureHelix™ Genomic Prep Kit [Bacteria] (Solution based)
- Pre-exposure prophylaxis (PrEP) usage among cisgender and transgender women sex workers in Europe is low. This mixed-methods study examined the daily experiences of woman sex workers using PrEP, with emphasis on understanding the dynamic process of initiating and sustaining PrEP adherence. We employed an intensive longitudinal design with daily assessments of self-reported use of daily oral PrEP, side-effects, condom use, and number of clients over a 3-month period, followed by in-depth exit qualitative interviews that also explored PrEP initiation, communication with sex workers and clients, and stigma. Convenience sampling was used to enroll 15 sex workers (12 transgender and 3 cisgender women) presenting to a PrEP clinic in Madrid between November 2022 and January 2023, all from Latin America. We collected 1266 daily survey responses and 13 interviews. Quantitative results showed that average PrEP adherence was above 70%, with missed doses being randomly distributed, and that condom use and number of clients did not significantly change during the study period. Qualitative results showed that the main reason to start PrEP was concern about condom rupture and/or removal by clients. Facilitators of PrEP adherence included personal motivation, creation of daily routines, and use of personal alarms. Barriers to PrEP adherence included side effects from PrEP and its coingestion with other substances, and changes in daily routine related to work, and travel. Strict prescription protocols represented an additional layer of difficulty. Secondary gains included a feeling of empowerment and the opportunity to opt for condom substitution for economic benefit, personal pleasure, or the desire to foster a trusting relationship with long-standing clients. This involved few selected encounters and did not impact overall number of clients. PrEP communication was limited by PrEP and HIV stigma. We found a complex interplay of individual, occupational, and structural factors shaping early PrEP adherence among participants. - Source: PubMed
Publication date: 2026/05/07
Vazquez Guillamet Laia JValencia JorgeRyan PabloMatarranz MarianoCuevas-Tascón GuillermoDel-Olmo-Morales Miguel AngelLaguna LauraCasanueva NataliaViladomiu CristinaMatthews Lynn TLazarus Jeffrey VChevance Guillaume - Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre-exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW). To address this gap, we examined drug metabolites in HIV susceptible cells isolated from blood and rectal tissues of TGW and CGW. - Source: PubMed
Publication date: 2026/05/07
Hastie ElizabethSrivasta MeghaCachay Edward RBurke LeahGianella SaraRawlings StephenStanczyk Frank ZSykes CraigKashuba Angela D MBlumenthal JillCottrell Mackenzie L - HIV remains a global health concern, disproportionately affecting men who have sex with men (MSM). Discrimination, stigma, and other barriers in healthcare settings are common issues for MSM in Malaysia, resulting in sub-optimal HIV testing and linkage to HIV prevention services. Thus, we created a clinic-integrated HIV prevention app called "JomPrEP" to scale up HIV prevention efforts among this vulnerable group. This study aimed to explore the perceived utility, appeal, and functionality of the JomPrEP app for MSM in Malaysia to improve access to HIV prevention services. - Source: PubMed
Publication date: 2026/05/04
Sujan Md Safaet HossainWickersham Jeffrey AKhati AntoineGautam KamalPaudel KiranAzwa IskandarAltice Frederick LTan Yee KeeSabri Nursahira Sahiba MohdCopenhaver Michael MShrestha Roman - Novel HIV prevention interventions such as long-acting pre-exposure prophylaxis (PrEP) could substantially reduce HIV transmission in Africa. However, efficient implementation in high-prevalence settings where incidence has declined requires an understanding of the contemporary dynamics driving new infections. - Source: PubMed
Publication date: 2026/04/30
Bell Griffin JGrabowski M KateMpagazi JosephineDi Lauro FrancescoKhalifa AleyaNdyanabo AnthonyNakawooya HadijjaKagaayi JosephKigozi GodfreyNakigozi GertrudeGaliwango Ronald MKigozi GraceMartin Michael AFerretti LucaFraser ChristopheBonsall DavidAbeler-Dörner LucieGolubchik TanyaTobian Aaron ArBeres Laura KKennedy CaitlinLessler JustinQuinn Thomas CReynolds Steven JWawer Maria JGray Ronald HSerwadda DavidChang Larry WSsekubugu Robert - Portugal has been committed to achieve UNAIDS target goals by the end of 2030 by improving accessibility of prevention programs to the general population and key populations. However, Portugal remains as one of the countries in the European Union with the highest annual number of reported HIV cases and the highest proportion of AIDS diagnosis. The main aim of this scoping review is to understand how knowledge and usage of primary and secondary prevention strategies are being assessed in Portugal across key populations, such as sex workers, men who have sex with men, people who inject drugs, migrants and transgender. - Source: PubMed
Publication date: 2026/05/07
Brázia JoãoWang BoxuanMeireles PaulaValdano EugenioTeixeira Andreia Sofia